Victoza 2-Pak (Liraglutide) — Medicare Part D spending
Novo Nordisk · Rank #159 by total Part D spend · CMS data year 2023
Medicare Part D spent $317,213,565 on Victoza 2-Pak (Liraglutide) in 2023, the #159 drug by total Part D spending out of 3,598 drugs. That worked out to about $126.64 per dosage unit, $1,081 per claim and $3,786 per beneficiary, across 293,462 claims for 83,777 beneficiaries. Average spending per dosage unit rose +3.7% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Victoza 2-Pak (Liraglutide) spending at a glance (2023)
| Metric | Victoza 2-Pak (Liraglutide) |
|---|---|
| Total Part D spending (2023) | $317,213,565 |
| Total spending (2022) | $319,205,509 |
| Year-over-year change in total spending | -0.6% |
| Average spending per dosage unit (2023) | $126.64 |
| Change in spend per dosage unit (YoY) | +3.7% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +5.1% |
| Average spending per claim (2023) | $1,081 |
| Average spending per beneficiary (2023) | $3,786 |
| Total claims (2023) | 293,462 |
| Beneficiaries (2023) | 83,777 |
| Total dosage units (2023) | 2,504,754 |
| Manufacturer(s) | Novo Nordisk |
| National rank by total spend (of 3,598 drugs) | #159 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $319,205,509 | $317,213,565 | -0.6% |
| Avg spend per dosage unit | $122.14 | $126.64 | +3.7% |
| Avg spend per claim | $1,035 | $1,081 | — |
| Avg spend per beneficiary | $3,856 | $3,786 | — |
| Total claims | 308,357 | 293,462 | — |
| Beneficiaries | 82,777 | 83,777 | — |
How Victoza 2-Pak compares with nearby drugs
Drugs with total Part D spending closest to Victoza 2-Pak (Liraglutide):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Victoza 2-Pak (Liraglutide) (this drug, #159) | $317,213,565 | $126.64 | +3.7% |
| Gattex (Teduglutide) (#157) | $330,401,875 | $35,921.06 | +0.4% |
| Aimovig Autoinjector (Erenumab-Aooe) (#158) | $326,938,686 | $778.19 | +6.3% |
| Dexlansoprazole Dr (Dexlansoprazole) (#160) | $315,328,215 | $7.36 | -10.5% |
| Ubrelvy (Ubrogepant) (#161) | $314,663,943 | $104.16 | +3.8% |
| Ninlaro (Ixazomib Citrate) (#162) | $311,982,549 | $4,346.07 | +7.8% |
Frequently asked questions
How much does Medicare Part D spend on Victoza 2-Pak?
Medicare Part D spent $317,213,565 on Victoza 2-Pak (Liraglutide) in 2023 (the latest CMS data year), across 293,462 claims for 83,777 beneficiaries. That ranks #159 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Victoza 2-Pak?
In 2023, the weighted average Medicare Part D spending per dosage unit for Victoza 2-Pak (Liraglutide) was $126.64. Compared with 2022 it rose +3.7%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Victoza 2-Pak?
CMS attributes Victoza 2-Pak (Liraglutide) to Novo Nordisk in the 2023 Part D spending file. Average spending per claim was $1,081 and per beneficiary $3,786.
Is the Victoza 2-Pak figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20